Effect of Imatinib on chronic myelogenous leukemia

ABSTRACT: The Philadelphia chromosome (Ph) encodes the oncogenic BCR-ABL1 tyrosine kinase, which is present in almost every patient with chronic myeloid leukemia. In this study, the tyrosine kinase inhibitor Imatinib was used for pharmacological inhibition of BCR-ABL1. Gene expression profiles of CML cell lines were analyzed in response to Imatinib treatment.

ORGANISM(S): Homo sapiens

PROVIDER: GSE24493 | GEO | 2010/10/10

SECONDARY ACCESSION(S): PRJNA132497

REPOSITORIES: GEO